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CASE REPORTMore immune dysregulation: Sarcoidosis
and chronic graft-versus-host disease after
allogeneic stem cell transplant
Iviensan F. Manalo, BS, India Ashton Miller, MD, and Loretta S. Davis, MD
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human leukocyte antigen; noncaseating granulomas; sarcoidosis.Fig 1. White firm atrophic plaques of the inframammary
skin.
Fig 2. Erythematous-to-violaceous papules with minimal
scale centered around an old, well-healed abdominal scar.
Abbreviations used:
GVHD: graft-versus-host disease
HLA: human leukocyte antigen
HSCTs: hematopoietic stem cell transplantsINTRODUCTION
Approximately 25,000 allogeneic hematopoietic
stem cell transplants (HSCTs) are performed
annually. Cutaneous complications are common
and include a spectrum of acute and chronic
graft-versus-host disease (GVHD). Mechanisms
implicated in the rare development of sarcoidosis
after HSCT include specific pretransplant condition-
ing regimens, possible donor-to-recipient trans-
mission, genetic predisposition of sarcoidosis, and
post-HSCT immune dysregulation.
REPORT OF A CASE
A 58-year-old woman with a history of polymyal-
gia rheumatica, myelofibrosis (27 months postallo-
geneic HSCT from her human leukocyte antigen
[HLA]-matched brother), hypothyroidism, GVHD of
the gut, and noncaseating granulomas on lung
biopsy, presented with the following new skin
findings: white, firm lesions under her breasts
(Fig 1) and an increasing number of asymptomatic
red scaly bumps on her bilateral forearms and trunk
(Fig 2). The lesions persisted despite use of
triamcinolone 0.1% ointment. She denied family
history of skin or lung disease. Her medications
included omeprazole, vitamin D, calcium, duloxe-
tine, levothyroxine, and alprazolam as needed.
Importantly, she had not received any immunosup-
pressive therapy for almost 1 year.
Physical examination found bilateral inframam-
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Table I. Characteristics of patients reported to have sarcoidosis after allogeneic HSCT
Study Heyll2 Sundar3 Tauro4 Morita5 Bhagat6 Gooneratne7 Pukiat8 Kushima9 Current case
Age (y) & Sex 34 M 37 F 36 F 55 F 51 F 45 F 51 M 47 M 64 F 58 F
Type of HSCT,
donor
Allo,
sibling
Allo, sibling Allo, sibling Allo, UD Allo Allo, UD Allo, UD Allo, UD Allo, UD Allo, sibling
Family history
of sarcoidosis
1Donor 1Donor 1Donor &
1Patient
None None None None None None None
Donor diagnosed
with sarcoid
before or after
the HSCT? (at
the time of
case publication)
Yes,
before
the
HSCT
Yes after
the HSCT
(Lymph node
biopsies with
noncaseating
granulomas)
Yes, before
the HSCT
(sarcoidosis
of the liver)
Unknown Unknown No No No Unknown No signs
or symptoms
of sarcoidosis
to date (31
months
posttransplant)
Underlying
disease
NHL B cell
lymphoma
CML FL CML MDS MDS CMML ATL MF
HLA A1, A2,
B8, B51,
DR4,
DR4
A(1,26), B(8,49),
Cw(7,-),
DRb1*03011,
DRb1*1302
A-24(9),
B-8 52(5),
C-7 16; DR-
17(3) 18(3)
DQ-2 4 DP-
Donor had
one locus
mismatch
HLA
phenotype
& genotype
(DRB1 locus)
Unknown Unknown Unknown A*0101, A*2501,
B*0801, B*1801,
DRB1*0301,
DRB1*1501,
DQB1*0201,
DQB1*0602
Unknown A*0301, B*0702,
B*5501, C*0702,
C*0304, DRB1*
1301, DRB1*
1501, DQB1*0602
Post-HSCT
period (mo)
3 18 21 6 6 12 20 22 16 27
Organs confirmed
to have non-
caseating
granulomatous
changes on
biopsy
Lung &
liver
Lung, (skin
biopsy not
done)
Bone marrow Mediastinal
lymph
nodes,
pleura, and
a piece of
lung
Lung Liver,
Skin: non-
caseating
granulomas
Liver Lymph nodes,
Skin: poorly
defined
granulomatous
inflammation in
the deep dermis
Lung,
mediastinal
lymph nodes,
Subcutaneous
mass in left
upper arm:
noncaseating
granulomas
Lung,
skin:
noncaseating
granulomas
Clinically evident
cutaneous
lesions reported
No Petechial rash
owing to
chronic GVHD
over lower
extremities;
skin bx not
done
No No No Purple-brown
firm skin
lesions on
limbs,
upper
back, right
cheek
No Papular rash
(cutaneous
chronic GVHD),
indurated
erythematous
plaque
(granulomatous)
Subcutaneous
mass in left
upper arm
Red papules
with minimal
scale on
forearms and
trunk; White
firm atrophic
patches inferior
to bilateral
breasts
Allo, Allogeneic; ATL, adult T-cell leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; FL, follicular lymphoma; MDS, myelodysplastic syndrome; MF, myelofibrosis;
NHL, non-Hodgkin’s lymphoma; UD, unrelated donor.
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140 Manalo, Miller, and Davisviolaceous guttatelike papules with minimal scale on
her bilateral dorsal forearms and lower back. The
papules were also becoming confluent around an
old scar on her abdomen. Biopsy of an inframam-
mary atrophic plaque found epidermal thinning and
atrophy, papillary dermal hyalinization and sclerosis,
telangiectasias, and sparse interstitial lymphocytic
infiltrate. Biopsies of the abdominal scar and forearm
found numerous epithelioid histiocytes and
multinucleated giant cells forming noncaseating
granulomas without polarizable material; special
stains were negative for organisms.
She received a diagnosis of cutaneous chronic
GVHD, manifested as lichen sclerosus, and
cutaneous and pulmonary sarcoidosis. Thirty-one
months after transplantation, her donor HLA-
matched brother did not have any signs or symptoms
of sarcoidosis.DISCUSSION
In 2014, the National Institutes of Health proposed
updated diagnostic requirements for chronic GVHD,
none of which include granulomatous phenome-
non.1 Thorough literature review found 9 cases of
sarcoidosis after allogeneic HSCT, all reported in
nondermatologic literature (Table I).2-9 Five of the
9 cases describe cutaneous findings, 4 of which
had cutaneous biopsies showing noncaseating
granulomas. An additional 5 cases of sarcoidosis
have been reported after autologous HSCT.10
Immune dysregulation, both donor derived and
de novo, after allogeneic HSCT is postulated to
provide the immunologic environment necessary
for the development of sarcoidosis. Additionally, 2
reported cases have confirmed donor-derived
sarcoidosis with chimerism analysis of sarcoidal
lesions.5,9 Genetic predisposition to sarcoidosis is
well established and frequently associated with HLA
types A1, B8, and DR3. Acute disease with good
prognosis is associated with HLA types DRB1*0301
and DQB1*0201, whereas prolonged disease course
with poor prognosis is associated with DRB1*1501
and DRB1*0602.11 Our patient and her healthy donor
possess these 2 poor-prognostic HLA types. One of
the donors in the 9 previously reported cases had
sarcoidosis after the marrow donation, whereas 2 of
the 9 had sarcoidosis diagnosed before the donation.
Based on these findings, our patient’s donor may be
at an increased risk for sarcoidosis.
Immune dysregulation after HSCT is well known
to manifest as a variety of forms of GVHD. Becausesarcoidosis is also attributed to immune dysregula-
tion, it is not surprising that this common
granulomatous dermatitis may be seen with
increased frequency after HSCT. Our case shows
the simultaneous presentation of chronic GVHD
in the form of lichen sclerosus and new-onset
sarcoidosis after HSCT. Dermatologists should add
sarcoidosis to the list of possible posttransplant
cutaneous eruptions, especially in patients with
susceptible HLA types. Further research including
analysis of specific HLA types, information always
available in the transplant population, may lead to a
better understanding of the risk factors and
pathogenesis of this granulomatous conundrum.
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